Pyxis Oncology Statistics
Want to see PYXS full AI Analyst Report?
Pyxis Oncology (PYXS) Stock Statistics & Valuation Metrics
Total Valuation
Pyxis Oncology has a market cap or net worth of $198.55M. The enterprise value is $154.93M.
- Market Cap
- $198.55M
- Enterprise Value
- $154.93M
Share Statistics
Pyxis Oncology has 119,607,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 119,607,860
- Owned by Insiders
- 14.48%
- Owned by Institutions
- 10.77%
Financial Efficiency
Pyxis Oncology’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -117.12%.
- Return on Equity (ROE)
- -1.49
- Return on Assets (ROA)
- -0.87
- Return on Invested Capital (ROIC)
- -117.12%
- Return on Capital Employed (ROCE)
- -1.20
- Revenue Per Employee
- 247.46K
- Profits Per Employee
- -1.42M
- Employee Count
- 56
- Asset Turnover
- 0.15
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Pyxis Oncology is -1.31. Pyxis Oncology’s PEG ratio is -0.08.
- PE Ratio
- -1.31
- PS Ratio
- 9.76
- PB Ratio
- 3.44
- Price to FCF
- -1.52
- Price to Operating Cash Flow
- -2.00
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Pyxis Oncology had revenue of 13.86M and earned -79.62M in profits. Earnings per share was -1.28.
- Revenue
- 13.86M
- Gross Profit
- 11.47M
- Operating Income
- -84.42M
- Pretax Income
- -78.23M
- Net Income
- -79.62M
- EBITDA
- -73.72M
- Earnings Per Share (EPS)
- -1.28
Cash Flow
In the last 12 months, operating cash flow was -70.93M and capital expenditures 0, giving a free cash flow of -70.93M billion.
- Operating Cash Flow
- -70.93M
- Free Cash Flow
- -70.93M
- Free Cash Flow per Share
- -0.85
Dividends & Yields
Pyxis Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -66.05%
- Earnings Yield
- -61.26%
Stock Price Statistics
- Beta
- 1.71
- 52-Week Price Change
- -58.91%
- 50-Day Moving Average
- 2.52
- 200-Day Moving Average
- 2.17
- Relative Strength Index (RSI)
- 36.21
- Average Volume (3m)
- 1.21M
Important Dates
Pyxis Oncology upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Pyxis Oncology as a current ratio of 3.41, with Debt / Equity ratio of 34.96%
- Current Ratio
- 3.41
- Quick Ratio
- 3.41
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.04
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Pyxis Oncology has paid 1.39M in taxes.
- Income Tax
- 1.39M
- Effective Tax Rate
- -0.02
Enterprise Valuation
Pyxis Oncology EV to EBITDA ratio is -1.47, with an EV/FCF ratio of -1.71.
- EV to Sales
- 10.96
- EV to EBITDA
- -1.47
- EV to Free Cash Flow
- -1.71
- EV to Operating Cash Flow
- -1.71
Balance Sheet
Pyxis Oncology has $55.57M in cash and marketable securities with $17.40M in debt, giving a net cash position of $38.17M billion.
- Cash & Marketable Securities
- $55.57M
- Total Debt
- $17.40M
- Net Cash
- $38.17M
- Net Cash Per Share
- $0.32
- Tangible Book Value Per Share
- $0.49
Margins
Gross margin is 99.76%, with operating margin of -807.83%, and net profit margin of -785.54%.
- Gross Margin
- 99.76%
- Operating Margin
- -807.83%
- Pretax Margin
- -775.55%
- Net Profit Margin
- -785.54%
- EBITDA Margin
- -747.30%
- EBIT Margin
- -780.43%
Analyst Forecast
The average price target for Pyxis Oncology is $8.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $8.71
- Price Target Upside
- 424.96% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- 291.42%
- EPS Growth Forecast
- 18.90%
Scores
- Smart Score
- 7
- AI Score
- 48
